Myriad Genetics Inc
MYGN3.890USD
-0.140-3.47%
Close 05/09, 16:00（ET）Quotes delayed by 15 min
358.66MMarket Cap
LossP/E TTM
More Details of Myriad Genetics Inc Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Company Info
Company codeMYGN
Company nameMyriad Genetics Inc
IPO dateOct 06, 1995
Founded at1992
CEOMr. Samraat S. (Sam) Raha
Number of employees2700
Security typeOrdinary Share
Fiscal year-endOct 06
Address322 North 2200 West
CitySALT LAKE CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code84116
Phone18015843600
Websitehttps://myriad.com/
Company codeMYGN
IPO dateOct 06, 1995
Founded at1992
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Legal Officer
Chief Legal Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
By RegionUSD
Name
Revenue
Proportion
United States
769.50M
91.87%
Rest of world
68.10M
8.13%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
Shareholder
Update time: Sun, May 4
Update time: Sun, May 4
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.47%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.29%
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.47%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.29%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
43.50%
Investment Advisor
34.79%
Hedge Fund
18.62%
Individual Investor
2.85%
Research Firm
2.67%
Pension Fund
1.14%
Bank and Trust
0.40%
Sovereign Wealth Fund
0.10%
Insurance Company
0.04%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
510
96.13M
104.30%
-2.66M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
2023Q1
483
85.87M
105.37%
-2.69M
2022Q4
490
83.72M
103.14%
-4.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
14.32M
15.68%
+446.35K
+3.22%
Dec 31, 2024
The Vanguard Group, Inc.
10.57M
11.58%
+279.38K
+2.71%
Dec 31, 2024
Wellington Management Company, LLP
6.00M
6.58%
-711.99K
-10.60%
Dec 31, 2024
State Street Global Advisors (US)
5.53M
6.05%
+822.26K
+17.48%
Dec 31, 2024
Millennium Management LLC
4.35M
4.76%
-831.32K
-16.06%
Dec 31, 2024
Glenview Capital Management, LLC
4.16M
4.55%
+2.90M
+229.55%
Dec 31, 2024
EARNEST Partners, LLC
3.97M
4.35%
+15.65K
+0.40%
Dec 31, 2024
Camber Capital Management LP
3.10M
3.4%
-850.00K
-21.52%
Dec 31, 2024
Artisan Partners Limited Partnership
2.77M
3.03%
+336.77K
+13.86%
Dec 31, 2024
Disciplined Growth Investors, Inc.
2.56M
2.8%
+29.14K
+1.15%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
Invesco Biotechnology & Genome ETF
1.95%
Global X Genomics & Biotechnology ETF
1.64%
WisdomTree BioRevolution Fund
0.64%
Invesco S&P SmallCap Health Care ETF
0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.31%
SPDR S&P Biotech ETF
0.27%
Strategas Global Policy Opportunities ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Inspire Small/Mid Cap ESG ETF
0.14%
SPDR S&P 600 Small Cap Value ETF
0.12%
View more
Invesco Biotechnology & Genome ETF
Proportion1.95%
Global X Genomics & Biotechnology ETF
Proportion1.64%
WisdomTree BioRevolution Fund
Proportion0.64%
Invesco S&P SmallCap Health Care ETF
Proportion0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.31%
SPDR S&P Biotech ETF
Proportion0.27%
Strategas Global Policy Opportunities ETF
Proportion0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.17%
Inspire Small/Mid Cap ESG ETF
Proportion0.14%
SPDR S&P 600 Small Cap Value ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data